LIMINATUS PHARMA, INC. (LIMN) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $5.60K; Additional Paid in CapitalUSD $41.70M; Retained Earnings (Accumulated Deficit)USD $-41.40M; Stockholders' Equity Attributable to ParentUSD $300.61K.
- 2026-03-31: Common Stock, Value, IssuedUSD $4.82K; Additional Paid in CapitalUSD $39.86M; Retained Earnings (Accumulated Deficit)USD $-40.00M; Stockholders' Equity Attributable to ParentUSD $-132.60K.
- 2025-12-31: Common Stock, Value, IssuedUSD $2.71K; Additional Paid in CapitalUSD $29.05M; Retained Earnings (Accumulated Deficit)USD $-38.87M; Stockholders' Equity Attributable to ParentUSD $-9.81M.
- 2025-09-30: Common Stock, Value, IssuedUSD $2.71K; Additional Paid in CapitalUSD $29.05M; Retained Earnings (Accumulated Deficit)USD $-30.70M; Stockholders' Equity Attributable to ParentUSD $-1.65M.
LIMINATUS PHARMA, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD |
|---|---|---|---|---|
| 2026-06-30 | $5.60K | $41.70M | $-41.40M | $300.61K |
| 2026-03-31 | $4.82K | $39.86M | $-40.00M | $-132.60K |
| 2025-12-31 | $2.71K | $29.05M | $-38.87M | $-9.81M |
| 2025-09-30 | $2.71K | $29.05M | $-30.70M | $-1.65M |
| 2025-06-30 | $2.60K | $20.07M | $-28.88M | $-8.81M |
| 2025-03-31 | $0.00 | $10.00 | $-1.06K | $-19.67M |
| 2024-12-31 | $1.75K | $9.32M | $-28.67M | $-19.34M |
| 2024-09-30 | (m) | (m) | (m) | $-19.11M |
| 2024-06-30 | (m) | (m) | (m) | $-18.51M |
| 2024-03-31 | (m) | (m) | (m) | $-17.55M |
| 2023-12-31 | (m) | (m) | (m) | $-15.79M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |